Vadadustat

Routes
Oral (PO)
Half-Life (t½)
PO: 5.8h
Formula
C14H11ClN2O4
Molecular Weight
306.7 g/mol
PubChem CID
23634441
Aliases
AKB-6548, Vafseo

Pharmacological Mechanism

A reversible inhibitor of HIF prolyl-4-hydroxylases PH1, PH2 and PH3. Vafseo label section 12.1 verbatim: "Vadadustat is a reversible inhibitor of HIF-prolyl-4-hydroxylases (PH)1, PH2, and PH3 (IC50 in the nM range). This activity results in the stabilization and nuclear accumulation of HIF-1alpha and HIF-2alpha transcription factors, and increased production of erythropoietin (EPO)." Its preclinical characterisation adds the kinetics of inhibition, verbatim (vadadustat the subject, PMID:35926869): "PHD enzyme inhibition by vadadustat is competitive with endogenous cofactor 2-oxoglutarate and is insensitive to free iron concentration." THAT PAPER SAYS ONLY "similar low nanomolar inhibitory constant values" AND PRINTS NO NUMBER, so no occupancy row is authored.

Half-Life & Elimination Curve (PO: 5.8h)

100%50%25%12.5%0%0h0×t½5.8h1×t½11.6h2×t½17.4h3×t½23.2h4×t½29h5×t½0×t½ (0h): 100% remaining1×t½ (5.8h): 50% remaining2×t½ (11.6h): 25% remaining3×t½ (17.4h): 12.5% remaining4×t½ (23.2h): 6.3% remaining5×t½ (29h): 3.1% remaining
Elimination (PO)
  • 0×t½0h100%
  • 1×t½5.8h50%
  • 2×t½11.6h25%
  • 3×t½17.4h12.5%
  • 4×t½23.2h6.3%
  • 5×t½29h3.1%
Elimination t½5.8h (PO)
Rate Constant (ke)0.12 h⁻¹
97% Washout (5×t½)29h

Dosing Guidelines

Pharmacokinetic Parameters

Target Organ Systems

Notes

PubChem CID 23634441 (C14H11ClN2O4, 306.70), re-queried 2026-09-26, matching the Vafseo label section 11 verbatim: "weight of 306.70. The empirical formula is C14H11ClN2O4." No salt form exists (PUGREST.NotFound for "vadadustat sodium"), so doses are the free acid. DOSES from the label: section 2.3, "The recommended starting dose is 300 mg orally once daily"; section 3 lists 150 mg, 300 mg and 450 mg film-coated tablets. FOUR POPULATIONS, FOUR HALF-LIVES, and mixing them is the trap this record is built to prevent: 4.5 h in healthy men (PMID:38924087, hedged, single-or-multiple); 5.8 h normal hepatic function at 450 mg single dose (PMID:33661566, stored); 7.2 h in CKD stage 3 and 8.5 h in CKD stage 4 after a single 500 mg dose, which are two populations and not a range (PMID:38924087); and from the label, "The mean half-life of vadadustat in patients on chronic hemodialysis was 13.9 hours" — nearly 3x the healthy figure and belonging to dialysis patients alone. AN UNREAD CORRECTION: PMID:38924087 has an erratum, PMID:39520093, whose own abstract carries no content, so what was corrected is unknown. That is the reason its 4.5 h is recorded here rather than stored. NO V, F, CL, Cmax OR AUC IS PUBLISHED ANYWHERE REACHED — absent from label section 12.3 and from every abstract fetched, and PMID:38924087 has no PMC copy, so its PK table is unread: full text NOT RETRIEVED, not silent.

Chemical Structure & Identifiers

References